#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2. Oxidative Modification of rRNA
1-1	0-2	2.	_	_	_	_
1-2	3-12	Oxidative	abstract[1]	new[1]	_	_
1-3	13-25	Modification	abstract[1]	new[1]	_	_
1-4	26-28	of	abstract[1]	new[1]	_	_
1-5	29-33	rRNA	abstract[1]|abstract	new[1]|new	coref	2-1

#Text=rRNA constitutes the structural and functional core of the ribosome .
2-1	34-38	rRNA	abstract	giv	coref	9-17
2-2	39-50	constitutes	_	_	_	_
2-3	51-54	the	abstract[4]	new[4]	_	_
2-4	55-65	structural	abstract[4]	new[4]	_	_
2-5	66-69	and	abstract[4]	new[4]	_	_
2-6	70-80	functional	abstract[4]	new[4]	_	_
2-7	81-85	core	abstract[4]	new[4]	_	_
2-8	86-88	of	abstract[4]	new[4]	_	_
2-9	89-92	the	abstract[4]|object[5]	new[4]|new[5]	coref	9-2[0_5]
2-10	93-101	ribosome	abstract[4]|object[5]	new[4]|new[5]	_	_
2-11	102-103	.	_	_	_	_

#Text=ROS can affect RNA in a multitude of ways , including chemical modification of the base and sugar moieties , generation of abasic sites , and strand breaks .
3-1	104-107	ROS	substance	new	_	_
3-2	108-111	can	_	_	_	_
3-3	112-118	affect	_	_	_	_
3-4	119-122	RNA	substance	new	coref	7-10
3-5	123-125	in	_	_	_	_
3-6	126-127	a	abstract[8]	new[8]	_	_
3-7	128-137	multitude	abstract[8]	new[8]	_	_
3-8	138-140	of	abstract[8]	new[8]	_	_
3-9	141-145	ways	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-10	146-147	,	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-11	148-157	including	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-12	158-166	chemical	abstract[8]|abstract[9]|event[10]	new[8]|new[9]|new[10]	coref	21-15[183_10]
3-13	167-179	modification	abstract[8]|abstract[9]|event[10]	new[8]|new[9]|new[10]	_	_
3-14	180-182	of	abstract[8]|abstract[9]|event[10]	new[8]|new[9]|new[10]	_	_
3-15	183-186	the	abstract[8]|abstract[9]|event[10]|abstract[13]	new[8]|new[9]|new[10]|new[13]	_	_
3-16	187-191	base	abstract[8]|abstract[9]|event[10]|substance|abstract[13]	new[8]|new[9]|new[10]|new|new[13]	coref	6-22[36_0]
3-17	192-195	and	abstract[8]|abstract[9]|event[10]|abstract[13]	new[8]|new[9]|new[10]|new[13]	_	_
3-18	196-201	sugar	abstract[8]|abstract[9]|event[10]|substance|abstract[13]	new[8]|new[9]|new[10]|new|new[13]	_	_
3-19	202-210	moieties	abstract[8]|abstract[9]|event[10]|abstract[13]	new[8]|new[9]|new[10]|new[13]	_	_
3-20	211-212	,	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-21	213-223	generation	abstract[8]|abstract[9]|event[14]	new[8]|new[9]|new[14]	_	_
3-22	224-226	of	abstract[8]|abstract[9]|event[14]	new[8]|new[9]|new[14]	_	_
3-23	227-233	abasic	abstract[8]|abstract[9]|event[14]|abstract|place[16]	new[8]|new[9]|new[14]|new|new[16]	_	_
3-24	234-239	sites	abstract[8]|abstract[9]|event[14]|place[16]	new[8]|new[9]|new[14]|new[16]	_	_
3-25	240-241	,	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-26	242-245	and	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-27	246-252	strand	abstract[8]|abstract[9]|place|event[18]	new[8]|new[9]|new|new[18]	_	_
3-28	253-259	breaks	abstract[8]|abstract[9]|event[18]	new[8]|new[9]|new[18]	_	_
3-29	260-261	.	_	_	_	_

#Text=Guanine is the most easily oxidized nucleobase and best studied in this respect .
4-1	262-269	Guanine	abstract	new	coref	4-3[20_0]
4-2	270-272	is	_	_	_	_
4-3	273-276	the	abstract[20]	giv[20]	coref	5-5[0_20]
4-4	277-281	most	abstract[20]	giv[20]	_	_
4-5	282-288	easily	abstract[20]	giv[20]	_	_
4-6	289-297	oxidized	abstract[20]	giv[20]	_	_
4-7	298-308	nucleobase	abstract[20]	giv[20]	_	_
4-8	309-312	and	_	_	_	_
4-9	313-317	best	_	_	_	_
4-10	318-325	studied	_	_	_	_
4-11	326-328	in	_	_	_	_
4-12	329-333	this	abstract[21]	new[21]	_	_
4-13	334-341	respect	abstract[21]	new[21]	_	_
4-14	342-343	.	_	_	_	_

#Text=An oxidized form of guanine , 8-oxo-7,8-dihydroguanine ( 8-hydroxyguanine ; 8-oxo-G ) , is a ubiquitous oxidative lesion , readily detectable in cellular nucleic acids .
5-1	344-346	An	abstract[22]	new[22]	coref	5-15[27_22]
5-2	347-355	oxidized	abstract[22]	new[22]	_	_
5-3	356-360	form	abstract[22]	new[22]	_	_
5-4	361-363	of	abstract[22]	new[22]	_	_
5-5	364-371	guanine	abstract[22]|abstract	new[22]|giv	appos	5-7
5-6	372-373	,	_	_	_	_
5-7	374-398	8-oxo-7,8-dihydroguanine	abstract	giv	appos	5-9
5-8	399-400	(	_	_	_	_
5-9	401-417	8-hydroxyguanine	abstract	giv	_	_
5-10	418-419	;	_	_	_	_
5-11	420-427	8-oxo-G	abstract	new	coref	6-6
5-12	428-429	)	_	_	_	_
5-13	430-431	,	_	_	_	_
5-14	432-434	is	_	_	_	_
5-15	435-436	a	abstract[27]	giv[27]	_	_
5-16	437-447	ubiquitous	abstract[27]	giv[27]	_	_
5-17	448-457	oxidative	abstract[27]	giv[27]	_	_
5-18	458-464	lesion	abstract[27]	giv[27]	_	_
5-19	465-466	,	abstract[27]	giv[27]	_	_
5-20	467-474	readily	abstract[27]	giv[27]	_	_
5-21	475-485	detectable	abstract[27]	giv[27]	_	_
5-22	486-488	in	abstract[27]	giv[27]	_	_
5-23	489-497	cellular	abstract[27]|substance[28]	giv[27]|new[28]	_	_
5-24	498-505	nucleic	abstract[27]|substance[28]	giv[27]|new[28]	_	_
5-25	506-511	acids	abstract[27]|substance[28]	giv[27]|new[28]	_	_
5-26	512-513	.	_	_	_	_

#Text=When present in mRNA , 8-oxo-G interferes with decoding , possibly through the formation of a Hoogsteen pair with adenine when the base rotates around the N-glycosidic bond .
6-1	514-518	When	_	_	_	_
6-2	519-526	present	_	_	_	_
6-3	527-529	in	_	_	_	_
6-4	530-534	mRNA	abstract	new	_	_
6-5	535-536	,	_	_	_	_
6-6	537-544	8-oxo-G	abstract	giv	_	_
6-7	545-555	interferes	_	_	_	_
6-8	556-560	with	_	_	_	_
6-9	561-569	decoding	abstract	new	_	_
6-10	570-571	,	_	_	_	_
6-11	572-580	possibly	event[32]	new[32]	_	_
6-12	581-588	through	event[32]	new[32]	_	_
6-13	589-592	the	event[32]	new[32]	_	_
6-14	593-602	formation	event[32]	new[32]	_	_
6-15	603-605	of	event[32]	new[32]	_	_
6-16	606-607	a	event[32]|abstract[34]	new[32]|new[34]	_	_
6-17	608-617	Hoogsteen	event[32]|person|abstract[34]	new[32]|new|new[34]	_	_
6-18	618-622	pair	event[32]|abstract[34]	new[32]|new[34]	_	_
6-19	623-627	with	event[32]|abstract[34]	new[32]|new[34]	_	_
6-20	628-635	adenine	event[32]|abstract[34]|substance	new[32]|new[34]|new	_	_
6-21	636-640	when	_	_	_	_
6-22	641-644	the	substance[36]	giv[36]	_	_
6-23	645-649	base	substance[36]	giv[36]	_	_
6-24	650-657	rotates	_	_	_	_
6-25	658-664	around	_	_	_	_
6-26	665-668	the	abstract[37]	new[37]	_	_
6-27	669-681	N-glycosidic	abstract[37]	new[37]	_	_
6-28	682-686	bond	abstract[37]	new[37]	_	_
6-29	687-688	.	_	_	_	_

#Text=The altered base-pairing capacity of 8-oxo-G can also perturb RNA folding .
7-1	689-692	The	abstract[39]	new[39]	_	_
7-2	693-700	altered	abstract[39]	new[39]	_	_
7-3	701-713	base-pairing	abstract|abstract[39]	new|new[39]	_	_
7-4	714-722	capacity	abstract[39]	new[39]	_	_
7-5	723-725	of	abstract[39]	new[39]	_	_
7-6	726-733	8-oxo-G	abstract[39]|abstract	new[39]|new	coref	8-10
7-7	734-737	can	_	_	_	_
7-8	738-742	also	_	_	_	_
7-9	743-750	perturb	_	_	_	_
7-10	751-754	RNA	substance|event[42]	giv|new[42]	coref|coref	8-15|14-24[119_42]
7-11	755-762	folding	event[42]	new[42]	_	_
7-12	763-764	.	_	_	_	_

#Text=A recent study revealed a variety of outcomes when 8-oxo-G was incorporated into model RNA substrates , from stabilization of existing structural motifs to their destabilization and rearrangements into new structures .
8-1	765-766	A	abstract[43]	new[43]	coref	13-2[100_43]
8-2	767-773	recent	abstract[43]	new[43]	_	_
8-3	774-779	study	abstract[43]	new[43]	_	_
8-4	780-788	revealed	_	_	_	_
8-5	789-790	a	abstract[44]	new[44]	_	_
8-6	791-798	variety	abstract[44]	new[44]	_	_
8-7	799-801	of	abstract[44]	new[44]	_	_
8-8	802-810	outcomes	abstract[44]|abstract	new[44]|new	_	_
8-9	811-815	when	_	_	_	_
8-10	816-823	8-oxo-G	abstract	giv	coref	13-20
8-11	824-827	was	_	_	_	_
8-12	828-840	incorporated	_	_	_	_
8-13	841-845	into	_	_	_	_
8-14	846-851	model	object[48]	new[48]	ana	8-25[0_48]
8-15	852-855	RNA	substance|object[48]	giv|new[48]	coref	11-13
8-16	856-866	substrates	object[48]	new[48]	_	_
8-17	867-868	,	_	_	_	_
8-18	869-873	from	_	_	_	_
8-19	874-887	stabilization	event[49]	new[49]	_	_
8-20	888-890	of	event[49]	new[49]	_	_
8-21	891-899	existing	event[49]|abstract[50]	new[49]|new[50]	_	_
8-22	900-910	structural	event[49]|abstract[50]	new[49]|new[50]	_	_
8-23	911-917	motifs	event[49]|abstract[50]	new[49]|new[50]	_	_
8-24	918-920	to	_	_	_	_
8-25	921-926	their	object|abstract[52]	giv|new[52]	_	_
8-26	927-942	destabilization	abstract[52]	new[52]	_	_
8-27	943-946	and	_	_	_	_
8-28	947-961	rearrangements	abstract[53]	new[53]	_	_
8-29	962-966	into	abstract[53]	new[53]	_	_
8-30	967-970	new	abstract[53]|abstract[54]	new[53]|new[54]	_	_
8-31	971-981	structures	abstract[53]|abstract[54]	new[53]|new[54]	_	_
8-32	982-983	.	_	_	_	_

#Text=Since ribosome activities in translation depend on many precisely tuned conformational changes and movements within its rRNA framework , oxidation of the bases that are critical for maintaining the correct rRNA structure may impair ribosome functions .
9-1	984-989	Since	_	_	_	_
9-2	990-998	ribosome	object|abstract[56]	giv|new[56]	coref	9-35
9-3	999-1009	activities	abstract[56]	new[56]	_	_
9-4	1010-1012	in	abstract[56]	new[56]	_	_
9-5	1013-1024	translation	abstract[56]|abstract	new[56]|new	ana	9-16
9-6	1025-1031	depend	_	_	_	_
9-7	1032-1034	on	_	_	_	_
9-8	1035-1039	many	abstract[58]	new[58]	_	_
9-9	1040-1049	precisely	abstract[58]	new[58]	_	_
9-10	1050-1055	tuned	abstract[58]	new[58]	_	_
9-11	1056-1070	conformational	abstract[58]	new[58]	_	_
9-12	1071-1078	changes	abstract[58]	new[58]	_	_
9-13	1079-1082	and	_	_	_	_
9-14	1083-1092	movements	abstract[59]	new[59]	_	_
9-15	1093-1099	within	abstract[59]	new[59]	_	_
9-16	1100-1103	its	abstract[59]|abstract|abstract[62]	new[59]|giv|new[62]	_	_
9-17	1104-1108	rRNA	abstract[59]|abstract|abstract[62]	new[59]|giv|new[62]	coref	9-31
9-18	1109-1118	framework	abstract[59]|abstract[62]	new[59]|new[62]	_	_
9-19	1119-1120	,	_	_	_	_
9-20	1121-1130	oxidation	event[63]	new[63]	coref	10-14[0_63]
9-21	1131-1133	of	event[63]	new[63]	_	_
9-22	1134-1137	the	event[63]|abstract[64]	new[63]|new[64]	_	_
9-23	1138-1143	bases	event[63]|abstract[64]	new[63]|new[64]	_	_
9-24	1144-1148	that	event[63]|abstract[64]	new[63]|new[64]	_	_
9-25	1149-1152	are	event[63]|abstract[64]	new[63]|new[64]	_	_
9-26	1153-1161	critical	event[63]|abstract[64]	new[63]|new[64]	_	_
9-27	1162-1165	for	_	_	_	_
9-28	1166-1177	maintaining	_	_	_	_
9-29	1178-1181	the	abstract[66]	new[66]	ana	10-1[0_66]
9-30	1182-1189	correct	abstract[66]	new[66]	_	_
9-31	1190-1194	rRNA	abstract|abstract[66]	giv|new[66]	coref	11-8[79_0]
9-32	1195-1204	structure	abstract[66]	new[66]	_	_
9-33	1205-1208	may	_	_	_	_
9-34	1209-1215	impair	_	_	_	_
9-35	1216-1224	ribosome	object|abstract[68]	giv|new[68]	coref	10-25[76_0]
9-36	1225-1234	functions	abstract[68]	new[68]	_	_
9-37	1235-1236	.	_	_	_	_

#Text=It seems therefore likely that the need to withstand a certain degree of oxidation was one of the forces in shaping the evolution of the ribosome .
10-1	1237-1239	It	abstract	giv	_	_
10-2	1240-1245	seems	_	_	_	_
10-3	1246-1255	therefore	_	_	_	_
10-4	1256-1262	likely	_	_	_	_
10-5	1263-1267	that	_	_	_	_
10-6	1268-1271	the	abstract[70]	new[70]	_	_
10-7	1272-1276	need	abstract[70]	new[70]	_	_
10-8	1277-1279	to	abstract[70]	new[70]	_	_
10-9	1280-1289	withstand	abstract[70]	new[70]	_	_
10-10	1290-1291	a	abstract[70]|abstract[71]	new[70]|new[71]	_	_
10-11	1292-1299	certain	abstract[70]|abstract[71]	new[70]|new[71]	_	_
10-12	1300-1306	degree	abstract[70]|abstract[71]	new[70]|new[71]	_	_
10-13	1307-1309	of	abstract[70]|abstract[71]	new[70]|new[71]	_	_
10-14	1310-1319	oxidation	abstract[70]|abstract[71]|event	new[70]|new[71]|giv	coref	12-4[89_0]
10-15	1320-1323	was	_	_	_	_
10-16	1324-1327	one	abstract[73]	new[73]	_	_
10-17	1328-1330	of	abstract[73]	new[73]	_	_
10-18	1331-1334	the	abstract[73]|abstract[74]	new[73]|new[74]	_	_
10-19	1335-1341	forces	abstract[73]|abstract[74]	new[73]|new[74]	_	_
10-20	1342-1344	in	abstract[73]|abstract[74]	new[73]|new[74]	_	_
10-21	1345-1352	shaping	abstract[73]|abstract[74]	new[73]|new[74]	_	_
10-22	1353-1356	the	abstract[73]|abstract[74]|abstract[75]	new[73]|new[74]|new[75]	_	_
10-23	1357-1366	evolution	abstract[73]|abstract[74]|abstract[75]	new[73]|new[74]|new[75]	_	_
10-24	1367-1369	of	abstract[73]|abstract[74]|abstract[75]	new[73]|new[74]|new[75]	_	_
10-25	1370-1373	the	abstract[73]|abstract[74]|abstract[75]|object[76]	new[73]|new[74]|new[75]|giv[76]	_	_
10-26	1374-1382	ribosome	abstract[73]|abstract[74]|abstract[75]|object[76]	new[73]|new[74]|new[75]|giv[76]	_	_
10-27	1383-1384	.	_	_	_	_

#Text=A striking disappearance of many guanines from mitochondrial rRNA and reduced overall RNA content may be two such evolutionary adaptations that “ hardened ” mitoribosomes against damage from the abundant ROS generated inside mitochondria .
11-1	1385-1386	A	abstract[77]	new[77]	coref	11-17[82_77]
11-2	1387-1395	striking	abstract[77]	new[77]	_	_
11-3	1396-1409	disappearance	abstract[77]	new[77]	_	_
11-4	1410-1412	of	abstract[77]	new[77]	_	_
11-5	1413-1417	many	abstract[77]|substance[78]	new[77]|new[78]	_	_
11-6	1418-1426	guanines	abstract[77]|substance[78]	new[77]|new[78]	_	_
11-7	1427-1431	from	abstract[77]|substance[78]	new[77]|new[78]	_	_
11-8	1432-1445	mitochondrial	abstract[77]|substance[78]|abstract[79]	new[77]|new[78]|giv[79]	coref	13-28[0_79]
11-9	1446-1450	rRNA	abstract[77]|substance[78]|abstract[79]	new[77]|new[78]|giv[79]	_	_
11-10	1451-1454	and	abstract[77]|substance[78]	new[77]|new[78]	_	_
11-11	1455-1462	reduced	abstract[77]|substance[78]|abstract[81]	new[77]|new[78]|new[81]	coref	17-1[139_81]
11-12	1463-1470	overall	abstract[77]|substance[78]|abstract[81]	new[77]|new[78]|new[81]	_	_
11-13	1471-1474	RNA	abstract[77]|substance[78]|substance|abstract[81]	new[77]|new[78]|giv|new[81]	coref	12-5
11-14	1475-1482	content	abstract[77]|substance[78]|abstract[81]	new[77]|new[78]|new[81]	_	_
11-15	1483-1486	may	_	_	_	_
11-16	1487-1489	be	_	_	_	_
11-17	1490-1493	two	abstract[82]	giv[82]	_	_
11-18	1494-1498	such	abstract[82]	giv[82]	_	_
11-19	1499-1511	evolutionary	abstract[82]	giv[82]	_	_
11-20	1512-1523	adaptations	abstract[82]	giv[82]	_	_
11-21	1524-1528	that	abstract[82]	giv[82]	_	_
11-22	1529-1530	“	abstract[82]	giv[82]	_	_
11-23	1531-1539	hardened	abstract[82]	giv[82]	_	_
11-24	1540-1541	”	abstract[82]	giv[82]	_	_
11-25	1542-1555	mitoribosomes	abstract[82]|animal	giv[82]|new	_	_
11-26	1556-1563	against	abstract[82]	giv[82]	_	_
11-27	1564-1570	damage	abstract[82]|abstract[84]	giv[82]|new[84]	coref	12-27[95_84]
11-28	1571-1575	from	abstract[82]|abstract[84]	giv[82]|new[84]	_	_
11-29	1576-1579	the	abstract[82]|abstract[84]|substance[85]	giv[82]|new[84]|new[85]	_	_
11-30	1580-1588	abundant	abstract[82]|abstract[84]|substance[85]	giv[82]|new[84]|new[85]	_	_
11-31	1589-1592	ROS	abstract[82]|abstract[84]|substance[85]	giv[82]|new[84]|new[85]	_	_
11-32	1593-1602	generated	abstract[82]|abstract[84]|substance[85]	giv[82]|new[84]|new[85]	_	_
11-33	1603-1609	inside	abstract[82]|abstract[84]|substance[85]	giv[82]|new[84]|new[85]	_	_
11-34	1610-1622	mitochondria	abstract[82]|abstract[84]|substance[85]|animal	giv[82]|new[84]|new[85]|new	_	_
11-35	1623-1624	.	_	_	_	_

#Text=The extent of cellular RNA oxidation was reported to exceed that of DNA when cells were directly treated with H2O2 or subjected to conditions that induce secondary oxidative damage , such as UVA irradiation and ammonia overload .
12-1	1625-1628	The	abstract[87]	new[87]	ana	12-11[90_87]
12-2	1629-1635	extent	abstract[87]	new[87]	_	_
12-3	1636-1638	of	abstract[87]	new[87]	_	_
12-4	1639-1647	cellular	abstract[87]|event[89]	new[87]|giv[89]	_	_
12-5	1648-1651	RNA	abstract[87]|substance|event[89]	new[87]|giv|giv[89]	coref	13-24
12-6	1652-1661	oxidation	abstract[87]|event[89]	new[87]|giv[89]	_	_
12-7	1662-1665	was	_	_	_	_
12-8	1666-1674	reported	_	_	_	_
12-9	1675-1677	to	_	_	_	_
12-10	1678-1684	exceed	_	_	_	_
12-11	1685-1689	that	abstract[90]	giv[90]	_	_
12-12	1690-1692	of	abstract[90]	giv[90]	_	_
12-13	1693-1696	DNA	abstract[90]|abstract	giv[90]|new	_	_
12-14	1697-1701	when	_	_	_	_
12-15	1702-1707	cells	animal	new	coref	13-7[104_0]
12-16	1708-1712	were	_	_	_	_
12-17	1713-1721	directly	_	_	_	_
12-18	1722-1729	treated	_	_	_	_
12-19	1730-1734	with	_	_	_	_
12-20	1735-1739	H2O2	abstract	new	coref	13-11
12-21	1740-1742	or	_	_	_	_
12-22	1743-1752	subjected	_	_	_	_
12-23	1753-1755	to	_	_	_	_
12-24	1756-1766	conditions	abstract[94]	new[94]	coref	20-52[177_94]
12-25	1767-1771	that	abstract[94]	new[94]	_	_
12-26	1772-1778	induce	abstract[94]	new[94]	_	_
12-27	1779-1788	secondary	abstract[94]|abstract[95]	new[94]|giv[95]	coref	14-32[122_95]
12-28	1789-1798	oxidative	abstract[94]|abstract[95]	new[94]|giv[95]	_	_
12-29	1799-1805	damage	abstract[94]|abstract[95]	new[94]|giv[95]	_	_
12-30	1806-1807	,	abstract[94]|abstract[95]	new[94]|giv[95]	_	_
12-31	1808-1812	such	abstract[94]|abstract[95]	new[94]|giv[95]	_	_
12-32	1813-1815	as	abstract[94]|abstract[95]	new[94]|giv[95]	_	_
12-33	1816-1819	UVA	abstract[94]|abstract[95]|substance|abstract[97]	new[94]|giv[95]|new|new[97]	_	_
12-34	1820-1831	irradiation	abstract[94]|abstract[95]|abstract[97]	new[94]|giv[95]|new[97]	_	_
12-35	1832-1835	and	abstract[94]|abstract[95]	new[94]|giv[95]	_	_
12-36	1836-1843	ammonia	abstract[94]|abstract[95]|substance|event[99]	new[94]|giv[95]|new|new[99]	_	_
12-37	1844-1852	overload	abstract[94]|abstract[95]|event[99]	new[94]|giv[95]|new[99]	_	_
12-38	1853-1854	.	_	_	_	_

#Text=In one study , exposure of E. coli cells to H2O2 was shown to induce a dosage-dependent increase of 8-oxo-G in all tested RNA types , including rRNA .
13-1	1855-1857	In	_	_	_	_
13-2	1858-1861	one	abstract[100]	giv[100]	coref	14-19[118_100]
13-3	1862-1867	study	abstract[100]	giv[100]	_	_
13-4	1868-1869	,	_	_	_	_
13-5	1870-1878	exposure	event[101]	new[101]	_	_
13-6	1879-1881	of	event[101]	new[101]	_	_
13-7	1882-1884	E.	event[101]|person|animal[104]	new[101]|new|giv[104]	coref|coref	15-21|15-20[132_104]
13-8	1885-1889	coli	event[101]|substance|animal[104]	new[101]|new|giv[104]	coref	15-21[131_0]
13-9	1890-1895	cells	event[101]|animal[104]	new[101]|giv[104]	_	_
13-10	1896-1898	to	event[101]	new[101]	_	_
13-11	1899-1903	H2O2	event[101]|abstract	new[101]|giv	coref	14-8
13-12	1904-1907	was	_	_	_	_
13-13	1908-1913	shown	_	_	_	_
13-14	1914-1916	to	_	_	_	_
13-15	1917-1923	induce	_	_	_	_
13-16	1924-1925	a	event[106]	new[106]	_	_
13-17	1926-1942	dosage-dependent	event[106]	new[106]	_	_
13-18	1943-1951	increase	event[106]	new[106]	_	_
13-19	1952-1954	of	event[106]	new[106]	_	_
13-20	1955-1962	8-oxo-G	event[106]|abstract	new[106]|giv	coref	14-3
13-21	1963-1965	in	event[106]	new[106]	_	_
13-22	1966-1969	all	event[106]|abstract[109]	new[106]|new[109]	_	_
13-23	1970-1976	tested	event[106]|abstract[109]	new[106]|new[109]	_	_
13-24	1977-1980	RNA	event[106]|substance|abstract[109]	new[106]|giv|new[109]	coref	15-17[128_0]
13-25	1981-1986	types	event[106]|abstract[109]	new[106]|new[109]	_	_
13-26	1987-1988	,	event[106]|abstract[109]	new[106]|new[109]	_	_
13-27	1989-1998	including	event[106]|abstract[109]	new[106]|new[109]	_	_
13-28	1999-2003	rRNA	event[106]|abstract[109]|abstract	new[106]|new[109]|giv	coref	14-26
13-29	2004-2005	.	_	_	_	_

#Text=By comparing 8-oxo-G levels after in vitro H2O2 treatment of RNAs in their native and denatured forms , the same study concluded that folding of rRNA did not protect it against oxidative damage .
14-1	2006-2008	By	_	_	_	_
14-2	2009-2018	comparing	_	_	_	_
14-3	2019-2026	8-oxo-G	abstract|abstract[112]	giv|new[112]	coref|coref	15-13|18-1[154_112]
14-4	2027-2033	levels	abstract[112]	new[112]	_	_
14-5	2034-2039	after	_	_	_	_
14-6	2040-2042	in	_	_	_	_
14-7	2043-2048	vitro	event[114]	new[114]	_	_
14-8	2049-2053	H2O2	abstract|event[114]	giv|new[114]	_	_
14-9	2054-2063	treatment	event[114]	new[114]	_	_
14-10	2064-2066	of	event[114]	new[114]	_	_
14-11	2067-2071	RNAs	event[114]|substance[115]	new[114]|new[115]	ana	14-13[0_115]
14-12	2072-2074	in	event[114]|substance[115]	new[114]|new[115]	_	_
14-13	2075-2080	their	event[114]|substance[115]|substance|substance[117]	new[114]|new[115]|giv|new[117]	_	_
14-14	2081-2087	native	event[114]|substance[115]|substance[117]	new[114]|new[115]|new[117]	_	_
14-15	2088-2091	and	event[114]|substance[115]|substance[117]	new[114]|new[115]|new[117]	_	_
14-16	2092-2101	denatured	event[114]|substance[115]|substance[117]	new[114]|new[115]|new[117]	_	_
14-17	2102-2107	forms	event[114]|substance[115]|substance[117]	new[114]|new[115]|new[117]	_	_
14-18	2108-2109	,	_	_	_	_
14-19	2110-2113	the	abstract[118]	giv[118]	_	_
14-20	2114-2118	same	abstract[118]	giv[118]	_	_
14-21	2119-2124	study	abstract[118]	giv[118]	_	_
14-22	2125-2134	concluded	_	_	_	_
14-23	2135-2139	that	_	_	_	_
14-24	2140-2147	folding	event[119]	giv[119]	_	_
14-25	2148-2150	of	event[119]	giv[119]	_	_
14-26	2151-2155	rRNA	event[119]|abstract	giv[119]|giv	ana	14-30
14-27	2156-2159	did	_	_	_	_
14-28	2160-2163	not	_	_	_	_
14-29	2164-2171	protect	_	_	_	_
14-30	2172-2174	it	abstract	giv	coref	20-19
14-31	2175-2182	against	_	_	_	_
14-32	2183-2192	oxidative	abstract[122]	giv[122]	coref	20-47[175_122]
14-33	2193-2199	damage	abstract[122]	giv[122]	_	_
14-34	2200-2201	.	_	_	_	_

#Text=Similar conclusions were made by Willi and colleagues , who used an 8-oxo-G antibody to immunoprecipitate oxidized RNA from H2O2-treated E. coli cells .
15-1	2202-2209	Similar	abstract[123]	new[123]	_	_
15-2	2210-2221	conclusions	abstract[123]	new[123]	_	_
15-3	2222-2226	were	_	_	_	_
15-4	2227-2231	made	_	_	_	_
15-5	2232-2234	by	_	_	_	_
15-6	2235-2240	Willi	person	new	_	_
15-7	2241-2244	and	_	_	_	_
15-8	2245-2255	colleagues	person[125]	new[125]	_	_
15-9	2256-2257	,	person[125]	new[125]	_	_
15-10	2258-2261	who	person[125]	new[125]	_	_
15-11	2262-2266	used	person[125]	new[125]	_	_
15-12	2267-2269	an	person[125]|substance[127]	new[125]|new[127]	_	_
15-13	2270-2277	8-oxo-G	person[125]|abstract|substance[127]	new[125]|giv|new[127]	coref	17-2
15-14	2278-2286	antibody	person[125]|substance[127]	new[125]|new[127]	_	_
15-15	2287-2289	to	_	_	_	_
15-16	2290-2307	immunoprecipitate	_	_	_	_
15-17	2308-2316	oxidized	substance[128]	giv[128]	coref	16-11[136_128]
15-18	2317-2320	RNA	substance[128]	giv[128]	_	_
15-19	2321-2325	from	_	_	_	_
15-20	2326-2338	H2O2-treated	substance|animal[132]	new|giv[132]	_	_
15-21	2339-2341	E.	person|substance[131]|animal[132]	giv|giv[131]|giv[132]	_	_
15-22	2342-2346	coli	substance[131]|animal[132]	giv[131]|giv[132]	_	_
15-23	2347-2352	cells	animal[132]	giv[132]	_	_
15-24	2353-2354	.	_	_	_	_

#Text=A large body of observations points to the association of oxidized RNA with disease .
16-1	2355-2356	A	object[133]	new[133]	coref	17-38[152_133]
16-2	2357-2362	large	object[133]	new[133]	_	_
16-3	2363-2367	body	object[133]	new[133]	_	_
16-4	2368-2370	of	object[133]	new[133]	_	_
16-5	2371-2383	observations	object[133]|abstract	new[133]|new	_	_
16-6	2384-2390	points	_	_	_	_
16-7	2391-2393	to	_	_	_	_
16-8	2394-2397	the	abstract[135]	new[135]	_	_
16-9	2398-2409	association	abstract[135]	new[135]	_	_
16-10	2410-2412	of	abstract[135]	new[135]	_	_
16-11	2413-2421	oxidized	abstract[135]|substance[136]	new[135]|giv[136]	coref	17-5[140_136]
16-12	2422-2425	RNA	abstract[135]|substance[136]	new[135]|giv[136]	_	_
16-13	2426-2430	with	abstract[135]	new[135]	_	_
16-14	2431-2438	disease	abstract[135]|abstract	new[135]|new	coref	17-15[143_0]
16-15	2439-2440	.	_	_	_	_

#Text=High 8-oxo-G content in cytoplasmic and nucleolar RNA was found in vulnerable neurons in Alzheimer ′s disease ( AD ) , Parkinson ’s disease , and neurons of the hippocampal region and temporal neocortex in patients with Lewy body dementia .
17-1	2441-2445	High	abstract[139]	giv[139]	_	_
17-2	2446-2453	8-oxo-G	abstract|abstract[139]	giv|giv[139]	coref	18-4
17-3	2454-2461	content	abstract[139]	giv[139]	_	_
17-4	2462-2464	in	abstract[139]	giv[139]	_	_
17-5	2465-2476	cytoplasmic	abstract[139]|substance[140]	giv[139]|giv[140]	coref	18-6[0_140]
17-6	2477-2480	and	abstract[139]|substance[140]	giv[139]|giv[140]	_	_
17-7	2481-2490	nucleolar	abstract[139]|substance[140]	giv[139]|giv[140]	_	_
17-8	2491-2494	RNA	abstract[139]|substance[140]	giv[139]|giv[140]	_	_
17-9	2495-2498	was	_	_	_	_
17-10	2499-2504	found	_	_	_	_
17-11	2505-2507	in	_	_	_	_
17-12	2508-2518	vulnerable	animal[141]	new[141]	coref	17-27[147_141]
17-13	2519-2526	neurons	animal[141]	new[141]	_	_
17-14	2527-2529	in	animal[141]	new[141]	_	_
17-15	2530-2539	Alzheimer	animal[141]|person[142]|abstract[143]	new[141]|new[142]|giv[143]	appos	17-19[0_143]
17-16	2540-2542	′s	animal[141]|person[142]|abstract[143]	new[141]|new[142]|giv[143]	_	_
17-17	2543-2550	disease	animal[141]|abstract[143]	new[141]|giv[143]	_	_
17-18	2551-2552	(	_	_	_	_
17-19	2553-2555	AD	abstract	giv	coref	17-22[146_0]
17-20	2556-2557	)	_	_	_	_
17-21	2558-2559	,	_	_	_	_
17-22	2560-2569	Parkinson	person[145]|abstract[146]	new[145]|giv[146]	coref	21-21[0_146]
17-23	2570-2572	’s	person[145]|abstract[146]	new[145]|giv[146]	_	_
17-24	2573-2580	disease	abstract[146]	giv[146]	_	_
17-25	2581-2582	,	_	_	_	_
17-26	2583-2586	and	_	_	_	_
17-27	2587-2594	neurons	animal[147]	giv[147]	_	_
17-28	2595-2597	of	animal[147]	giv[147]	_	_
17-29	2598-2601	the	animal[147]|place[148]	giv[147]|new[148]	_	_
17-30	2602-2613	hippocampal	animal[147]|place[148]	giv[147]|new[148]	_	_
17-31	2614-2620	region	animal[147]|place[148]	giv[147]|new[148]	_	_
17-32	2621-2624	and	animal[147]	giv[147]	_	_
17-33	2625-2633	temporal	animal[147]|place[149]	giv[147]|new[149]	_	_
17-34	2634-2643	neocortex	animal[147]|place[149]	giv[147]|new[149]	_	_
17-35	2644-2646	in	animal[147]	giv[147]	_	_
17-36	2647-2655	patients	animal[147]|person[150]	giv[147]|new[150]	coref	21-19[184_150]
17-37	2656-2660	with	animal[147]|person[150]	giv[147]|new[150]	_	_
17-38	2661-2665	Lewy	animal[147]|person[150]|person|object[152]|abstract[153]	giv[147]|new[150]|new|giv[152]|new[153]	_	_
17-39	2666-2670	body	animal[147]|person[150]|object[152]|abstract[153]	giv[147]|new[150]|giv[152]|new[153]	_	_
17-40	2671-2679	dementia	animal[147]|person[150]|abstract[153]	giv[147]|new[150]|new[153]	_	_
17-41	2680-2681	.	_	_	_	_

#Text=Elevated levels of 8-oxo-G in RNA were also detected in neuropsychiatric disorders , including schizophrenia , depressive , and bipolar disorders .
18-1	2682-2690	Elevated	abstract[154]	giv[154]	_	_
18-2	2691-2697	levels	abstract[154]	giv[154]	_	_
18-3	2698-2700	of	abstract[154]	giv[154]	_	_
18-4	2701-2708	8-oxo-G	abstract[154]|abstract	giv[154]|giv	coref	19-12
18-5	2709-2711	in	abstract[154]	giv[154]	_	_
18-6	2712-2715	RNA	abstract[154]|substance	giv[154]|giv	coref	19-3[161_0]
18-7	2716-2720	were	_	_	_	_
18-8	2721-2725	also	_	_	_	_
18-9	2726-2734	detected	_	_	_	_
18-10	2735-2737	in	_	_	_	_
18-11	2738-2754	neuropsychiatric	abstract[157]	new[157]	coref	18-20[160_157]
18-12	2755-2764	disorders	abstract[157]	new[157]	_	_
18-13	2765-2766	,	abstract[157]	new[157]	_	_
18-14	2767-2776	including	abstract[157]	new[157]	_	_
18-15	2777-2790	schizophrenia	abstract[157]|abstract	new[157]|new	_	_
18-16	2791-2792	,	abstract[157]	new[157]	_	_
18-17	2793-2803	depressive	abstract[157]|abstract	new[157]|new	_	_
18-18	2804-2805	,	abstract[157]	new[157]	_	_
18-19	2806-2809	and	abstract[157]	new[157]	_	_
18-20	2810-2817	bipolar	abstract[157]|abstract[160]	new[157]|giv[160]	_	_
18-21	2818-2827	disorders	abstract[157]|abstract[160]	new[157]|giv[160]	_	_
18-22	2828-2829	.	_	_	_	_

#Text=Furthermore , RNA extracted from atherosclerotic plaques was heavily modified with 8-oxo-G .
19-1	2830-2841	Furthermore	_	_	_	_
19-2	2842-2843	,	_	_	_	_
19-3	2844-2847	RNA	substance[161]	giv[161]	coref	20-16[168_161]
19-4	2848-2857	extracted	substance[161]	giv[161]	_	_
19-5	2858-2862	from	substance[161]	giv[161]	_	_
19-6	2863-2878	atherosclerotic	substance[161]|object[162]	giv[161]|new[162]	_	_
19-7	2879-2886	plaques	substance[161]|object[162]	giv[161]|new[162]	_	_
19-8	2887-2890	was	_	_	_	_
19-9	2891-2898	heavily	_	_	_	_
19-10	2899-2907	modified	_	_	_	_
19-11	2908-2912	with	_	_	_	_
19-12	2913-2920	8-oxo-G	abstract	giv	coref	20-4
19-13	2921-2922	.	_	_	_	_

#Text=Although links between 8-oxo-G and human pathologies have been based largely on the analysis of total RNA , rRNA is the most abundant cellular RNA type , which typically accounts for about 80 % of the total RNA , from which one can reasonably assume that oxidative damage to ribosomes in all these pathological conditions must be widespread .
20-1	2923-2931	Although	_	_	_	_
20-2	2932-2937	links	abstract[164]	new[164]	_	_
20-3	2938-2945	between	abstract[164]	new[164]	_	_
20-4	2946-2953	8-oxo-G	abstract[164]|abstract	new[164]|giv	coref	21-16
20-5	2954-2957	and	abstract[164]	new[164]	_	_
20-6	2958-2963	human	abstract[164]|abstract[166]	new[164]|new[166]	_	_
20-7	2964-2975	pathologies	abstract[164]|abstract[166]	new[164]|new[166]	_	_
20-8	2976-2980	have	_	_	_	_
20-9	2981-2985	been	_	_	_	_
20-10	2986-2991	based	_	_	_	_
20-11	2992-2999	largely	_	_	_	_
20-12	3000-3002	on	_	_	_	_
20-13	3003-3006	the	abstract[167]	new[167]	_	_
20-14	3007-3015	analysis	abstract[167]	new[167]	_	_
20-15	3016-3018	of	abstract[167]	new[167]	_	_
20-16	3019-3024	total	abstract[167]|substance[168]	new[167]|giv[168]	coref	20-24[170_168]
20-17	3025-3028	RNA	abstract[167]|substance[168]	new[167]|giv[168]	_	_
20-18	3029-3030	,	_	_	_	_
20-19	3031-3035	rRNA	abstract	giv	coref	20-21[171_0]
20-20	3036-3038	is	_	_	_	_
20-21	3039-3042	the	abstract[171]	giv[171]	ana	20-42[0_171]
20-22	3043-3047	most	abstract[171]	giv[171]	_	_
20-23	3048-3056	abundant	abstract[171]	giv[171]	_	_
20-24	3057-3065	cellular	substance[170]|abstract[171]	giv[170]|giv[171]	coref	20-36[173_170]
20-25	3066-3069	RNA	substance[170]|abstract[171]	giv[170]|giv[171]	_	_
20-26	3070-3074	type	abstract[171]	giv[171]	_	_
20-27	3075-3076	,	abstract[171]	giv[171]	_	_
20-28	3077-3082	which	abstract[171]	giv[171]	_	_
20-29	3083-3092	typically	abstract[171]	giv[171]	_	_
20-30	3093-3101	accounts	abstract[171]	giv[171]	_	_
20-31	3102-3105	for	abstract[171]	giv[171]	_	_
20-32	3106-3111	about	abstract[171]|abstract[172]	giv[171]|new[172]	_	_
20-33	3112-3114	80	abstract[171]|abstract[172]	giv[171]|new[172]	_	_
20-34	3115-3116	%	abstract[171]|abstract[172]	giv[171]|new[172]	_	_
20-35	3117-3119	of	abstract[171]|abstract[172]	giv[171]|new[172]	_	_
20-36	3120-3123	the	abstract[171]|abstract[172]|substance[173]	giv[171]|new[172]|giv[173]	_	_
20-37	3124-3129	total	abstract[171]|abstract[172]|substance[173]	giv[171]|new[172]|giv[173]	_	_
20-38	3130-3133	RNA	abstract[171]|abstract[172]|substance[173]	giv[171]|new[172]|giv[173]	_	_
20-39	3134-3135	,	abstract[171]	giv[171]	_	_
20-40	3136-3140	from	abstract[171]	giv[171]	_	_
20-41	3141-3146	which	abstract[171]	giv[171]	_	_
20-42	3147-3150	one	abstract[171]|abstract	giv[171]|giv	coref	21-6
20-43	3151-3154	can	abstract[171]	giv[171]	_	_
20-44	3155-3165	reasonably	abstract[171]	giv[171]	_	_
20-45	3166-3172	assume	abstract[171]	giv[171]	_	_
20-46	3173-3177	that	abstract[171]	giv[171]	_	_
20-47	3178-3187	oxidative	abstract[171]|abstract[175]	giv[171]|giv[175]	_	_
20-48	3188-3194	damage	abstract[171]|abstract[175]	giv[171]|giv[175]	_	_
20-49	3195-3197	to	abstract[171]|abstract[175]	giv[171]|giv[175]	_	_
20-50	3198-3207	ribosomes	abstract[171]|abstract[175]|object	giv[171]|giv[175]|new	_	_
20-51	3208-3210	in	abstract[171]|abstract[175]	giv[171]|giv[175]	_	_
20-52	3211-3214	all	abstract[171]|abstract[175]|abstract[177]	giv[171]|giv[175]|giv[177]	_	_
20-53	3215-3220	these	abstract[171]|abstract[175]|abstract[177]	giv[171]|giv[175]|giv[177]	_	_
20-54	3221-3233	pathological	abstract[171]|abstract[175]|abstract[177]	giv[171]|giv[175]|giv[177]	_	_
20-55	3234-3244	conditions	abstract[171]|abstract[175]|abstract[177]	giv[171]|giv[175]|giv[177]	_	_
20-56	3245-3249	must	abstract[171]	giv[171]	_	_
20-57	3250-3252	be	abstract[171]	giv[171]	_	_
20-58	3253-3263	widespread	abstract[171]	giv[171]	_	_
20-59	3264-3265	.	_	_	_	_

#Text=Studies that focused specifically on rRNA confirmed it to be a major target of the 8-oxo-G modification in patients with AD and mild cognitive impairment , a condition that often precedes AD .
21-1	3266-3273	Studies	abstract[178]	new[178]	_	_
21-2	3274-3278	that	abstract[178]	new[178]	_	_
21-3	3279-3286	focused	abstract[178]	new[178]	_	_
21-4	3287-3299	specifically	abstract[178]	new[178]	_	_
21-5	3300-3302	on	abstract[178]	new[178]	_	_
21-6	3303-3307	rRNA	abstract[178]|abstract	new[178]|giv	ana	21-8
21-7	3308-3317	confirmed	_	_	_	_
21-8	3318-3320	it	abstract	giv	_	_
21-9	3321-3323	to	_	_	_	_
21-10	3324-3326	be	_	_	_	_
21-11	3327-3328	a	abstract[181]	new[181]	_	_
21-12	3329-3334	major	abstract[181]	new[181]	_	_
21-13	3335-3341	target	abstract[181]	new[181]	_	_
21-14	3342-3344	of	abstract[181]	new[181]	_	_
21-15	3345-3348	the	abstract[181]|event[183]	new[181]|giv[183]	_	_
21-16	3349-3356	8-oxo-G	abstract[181]|abstract|event[183]	new[181]|giv|giv[183]	_	_
21-17	3357-3369	modification	abstract[181]|event[183]	new[181]|giv[183]	_	_
21-18	3370-3372	in	abstract[181]	new[181]	_	_
21-19	3373-3381	patients	abstract[181]|person[184]	new[181]|giv[184]	_	_
21-20	3382-3386	with	abstract[181]|person[184]	new[181]|giv[184]	_	_
21-21	3387-3389	AD	abstract[181]|person[184]|abstract	new[181]|giv[184]|giv	coref	21-32
21-22	3390-3393	and	abstract[181]|person[184]	new[181]|giv[184]	_	_
21-23	3394-3398	mild	abstract[181]|person[184]|abstract[186]	new[181]|giv[184]|new[186]	appos	21-27[187_186]
21-24	3399-3408	cognitive	abstract[181]|person[184]|abstract[186]	new[181]|giv[184]|new[186]	_	_
21-25	3409-3419	impairment	abstract[181]|person[184]|abstract[186]	new[181]|giv[184]|new[186]	_	_
21-26	3420-3421	,	_	_	_	_
21-27	3422-3423	a	abstract[187]	giv[187]	_	_
21-28	3424-3433	condition	abstract[187]	giv[187]	_	_
21-29	3434-3438	that	abstract[187]	giv[187]	_	_
21-30	3439-3444	often	abstract[187]	giv[187]	_	_
21-31	3445-3453	precedes	abstract[187]	giv[187]	_	_
21-32	3454-3456	AD	abstract[187]|abstract	giv[187]|giv	_	_
21-33	3457-3458	.	_	_	_	_
